Life Sciences

NERA is a pioneer in the field of economic and statistical analysis for clients in the global life sciences industry.  We are collaborating with law firms, pharmaceutical companies, medical device manufacturers, and diagnostic firms to address complex issues raised by legal disputes and regulatory challenges, devise strategies to manage tax burdens across jurisdictions, value liabilities, and advise firms on a range of economic issues related to life sciences.

Clients choose NERA because our experts have a strong history of providing independent, insightful, and comprehensive analysis and guidance in the pharmaceutical, biotechnology, medical device, and diagnostics industries. We work with the world’s top law firms, life sciences companies, regulators, tax authorities, and other entities to:

  • Determine the value of patents and other intellectual property, and advise firms in license negotiations
  • Consult on economic issues involving patent, product liability, mass tort, false claims, breach of contract, antitrust, securities, and trade secrets litigation, including forecasting future liabilities
  • Develop strategies to manage national and global tax exposure and address inquiries from tax authorities
  • Address competition and antitrust issues arising as part of reviews being undertaken by state, national, and global authorities, and from private litigation
  • Advise and provide expert analysis in the class certification, liability, and damages phases of antitrust, securities, and product liability class actions
  • Provide economic and statistical analysis of causation and damages in government investigations and litigation involving claims of fraud, False Claims Act, and Anti-Kickback Statute violations
  • Assist in corporate bankruptcies, complex commercial litigation, business valuations, and other securities matters
  • Respond to financial market abuse investigations and defend against enforcement actions in alleged violations of anti-corruption, fraud, and securities laws

Please visit the firm's health care web page for additional information on our extensive background in health care mergers, antitrust, and complex litigation.

Name Title Location Phone Email
Dr. Lawrence Wu President San Francisco +1 415 291 1007 lawrence.wu@nera.com
Sarah Butler Senior Managing Director
Chair of NERA's Survey Research, Design, and Analysis Practice
San Francisco +1 415 291 1022 sarah.butler@nera.com
Richard J. Eichmann Senior Managing Director
Chair of NERA's Intellectual Property Practice
San Francisco
Los Angeles
+1 415 291 1033
+1 213 346 3009
richard.eichmann@nera.com
Dr. Yves Hervé Senior Managing Director Frankfurt +49 69 710 447 508 yves.herve@nera.com
Bradley A. Heys Senior Managing Director Toronto
New York City
+1 416 868 7312
+1 212 345 3000
brad.heys@nera.com
Dr. Vinita Juneja Senior Managing Director
Chair of NERA's White Collar, Investigations and Enforcement Practice
New York City
London
Toronto
+1 212 345 3148
+44 20 7659 8618
+1 416 868 7314
vinita.juneja@nera.com
Dr. Denise Neumann Martin Senior Managing Director Miami +1 305 808 7880 denise.martin@nera.com
Dr. Christine Siegwarth Meyer Senior Managing Director White Plains, NY +1 914 448 4119 christine.meyer@nera.com
Dr. Subramaniam (Subbu) Ramanarayanan Senior Managing Director New York City
Los Angeles
+1 212 345 0745
+1 213 346 3038
subbu.ramanarayanan@nera.com
Dr. Lauren Stiroh Senior Managing Director White Plains, NY +1 914 448 4143 lauren.stiroh@nera.com
Dr. David Blackburn Managing Director Washington, DC +1 202 466 9264 david.blackburn@nera.com
Kristopher Boushie Managing Director Washington, DC +1 202 466 9228 kristopher.boushie@nera.com
Philip de Homont Managing Director Frankfurt +49 69 710 447 502 philip.de.homont@nera.com
Robert Patton Managing Director Toronto
London
New York City
+1 416 868 7318
+44 20 7659 8620
+1 212 345 3000
robert.patton@nera.com
Dr. Vladimir Starkov Managing Director Chicago +1 312 573 2806 vladimir.starkov@nera.com
Mary Elizabeth C. Stern Managing Director White Plains, NY +1 914 448 4054 mary.elizabeth.stern@nera.com
Dr. Chris Stomberg Managing Director Washington, DC +1 202 466 9219 chris.stomberg@nera.com
Dr. Nicola Tosini Managing Director Berlin
Brussels
Milan
+49 30 700 1506 70
+32 2 674 88 17
+39 345 3942428
nicola.tosini@nera.com
Dr. Paul Wong Managing Director San Francisco +1 415 291 1030 paul.wong@nera.com
Dr. Stephanie Child Director San Francisco +1 415 291 1070 stephanie.child@nera.com
Dr. Kate Foreman Director San Francisco +1 415 291 1000 kate.foreman@nera.com
Dr. Alan Grant Director Washington, DC +1 202 466 3510 alan.grant@nera.com
Dr. C.-Philipp Heller Director Berlin
London
Brussels
+49 30 700 1506 94
+44 20 7659 8500
+32 2 282 4340
philipp.heller@nera.com
Ralph Meghames Director Paris
Milan
+33 1 70 75 01 89
+39 02 305771
ralph.meghames@nera.com
Dr. Melissa Pittaoulis Director Philadelphia +1 215 864 3879 melissa.pittaoulis@nera.com
Bryan Ray Director White Plains, NY +1 914 448 4004 bryan.ray@nera.com
Ivelina Velikova Director New York City +1 212 345 1160 ivelina.velikova@nera.com
Healey Whitsett Director Washington, DC +1 202 466 9202 healey.whitsett@nera.com
Dr. Claire Chunying Xie Director Washington, DC +1 202 466 3510 claire.xie@nera.com
Dr. Rasmus Jørgensen Senior Consultant Washington, DC +1 (202) 466 9265 rasmus.jorgensen@nera.com
Alexis Jin Consultant Chicago +1 312 573 4804 alexis.jin@nera.com
Dr. Alan Cox Affiliated Consultant San Francisco +1 415 291 1000 alan.cox.affiliate@nera.com
Dr. Thomas McCarthy Affiliated Consultant Los Angeles +1 213 346 3000 thomas.mccarthy.affiliate@nera.com
Title Type Author
Americans' Health Priorities During the COVID-19 Pandemic Dr. Melissa Pittaoulis, Dr. Molly Sapia
The Role of Rebates in the Pharmaceutical Industry Published Article Dr. Chris Stomberg
Snapshot of Recent Trends in Asbestos Litigation 2021 Update Mary Elizabeth C. Stern and Lucy P. Allen
Economics in Life Sciences: Does Temporary Generic Competition Have a Lasting Impact ... Report Dr. David Blackburn and Dr. Rasmus Jørgensen
COVID-19 Fact Sheet: Vaccines, Treatments, and EUAs (First Quarter, 2021) Memo Dr. Chris Stomberg
Snapshot of Recent Trends in Asbestos Litigation: 2020 Update Report Mary Elizabeth C. Stern and Lucy P. Allen
Drug Rebates: A Peek Behind the Curtain at Drug Prices Published Article Dr. Christopher Stomberg
Snapshot of Recent Trends in Asbestos Litigation: 2019 Update Report Mary Elizabeth C. Stern and Lucy P. Allen
Glossary of Pharmaceutical Terms and Acronyms White Paper Dr. David Blackburn and Dr. Chris Stomberg
Generics and Back Margins: Why Is the Assessment Unchanged since 2013? White Paper Dr. Alexandre Carbonnel